-
FSCDR Presents Positive Results from Case Study of Voxelotor (GBT440) in Sickle Cell Disease Patient
Additional Photographs Added as of April 5, 2023. Some text has been updated to reflect present-day. HOLLYWOOD, Fla., — Oct. 31, 2017 — On Oct. 28, Lanetta Bronté-Hall, MD, MPH, MSPH presented a positive results case study for a sickle cell patient with severe and symptomatic anemia, after receiving voxelotor, at the 45th Annual…
Read More -
FSCDR’s Experience with Voxelotor (GBT440) Treatment in Patients with Severe Sickle Cell Disease
ATLANTA — Lanetta Bronté, M.D., M.P.H., M.S.P.H., founder and chief health officer of the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Fla., presented results from seven adult sickle cell disease patients with severe anemia and multiple co-morbidities who were not eligible to participate in Global Blood Therapeutics’s (GBT) Phase 3 HOPE (Hemoglobin…
Read More
